Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes

Fang, Chih-HaoChih-HaoFangWEN-FANG CHENGCheng, Ya-FangYa-FangChengLan, Keng-LiKeng-LiLanLee, Jan-MouJan-MouLee2024-04-262024-04-262024-03-281471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/642075Although immune cell therapy has long been used for treating solid cancer, its efficacy remains limited. Interferon (IFN)-producing killer dendritic cells (IKDCs) exhibit cytotoxicity and present antigens to relevant cells; thus, they can selectively induce tumor-associated antigen (TAA)-specific CD8 T cells and may be useful in cancer treatment. Various protocols have been used to amplify human IKDCs from peripheral sources, but the complexity of the process has prevented their widespread clinical application. Additionally, the induction of TAA-specific CD8 T cells through the adoptive transfer of IKDCs to immunocompromised patients with cancer may be insufficient. Therefore, we developed a method for generating an immune cell-based regimen, Phyduxon-T, comprising a human IKDC counterpart (Phyduxon) and expanded TAA-specific CD8 T cells.en4-1BB; IKDCs; Immunotherapy; Phyduxon-T; TAA-specific CD8 T cells[SDGs]SDG3[SDGs]SDG9Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytesjournal article10.1186/s12885-024-12101-3385490612-s2.0-85188780634https://api.elsevier.com/content/abstract/scopus_id/85188780634